Have a feature idea you'd love to see implemented?
Let us know!
BIOR Biora Therapeutics Inc
Price (delayed)
$1.63
Market cap
$7.37M
P/E Ratio
0.79
Dividend/share
N/A
EPS
$2.06
Enterprise value
$42.77M
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine.
Highlights
The EPS has soared by 105% from the previous quarter and by 102% YoY
The company's net income has surged by 74% YoY and by 64% QoQ
The equity has declined by 19% since the previous quarter but it is up by 10% year-on-year
BIOR's quick ratio has dropped by 83% year-on-year and by 75% since the previous quarter
Key stats
What are the main financial stats of BIOR
Market
Valuations
Earnings
Shares outstanding
4.52M
Market cap
$7.37M
Enterprise value
$42.77M
Price to earnings (P/E)
0.79
Price to book (P/B)
N/A
Price to sales (P/S)
6.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.95
Revenue
$892,000
EBIT
-$24.37M
EBITDA
-$23.93M
Free cash flow
-$46.18M
Per share
Balance sheet
Liquidity
EPS
$2.06
Free cash flow per share
-$12.64
Book value per share
-$29.24
Revenue per share
$0.24
TBVPS
$2.31
Total assets
$14.51M
Total liabilities
$121.13M
Debt
$38.59M
Equity
-$106.63M
Working capital
-$114.56M
Debt to equity
-0.36
Current ratio
0.05
Quick ratio
0.03
Net debt/EBITDA
-1.48
Margins
Efficiency
Dividend
EBITDA margin
-2,682.7%
Gross margin
100%
Net margin
-3,535.8%
Operating margin
-6,824.3%
Return on assets
-145.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-2,732.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIOR stock price
How has the Biora Therapeutics stock price performed over time
Intraday
0.62%
1 week
-31.51%
1 month
-64.1%
1 year
-87.74%
YTD
-87.93%
QTD
-67.53%
Financial performance
How have Biora Therapeutics's revenue and profit performed over time
Revenue
$892,000
Gross profit
$892,000
Operating income
-$60.87M
Net income
-$31.54M
Gross margin
100%
Net margin
-3,535.8%
Biora Therapeutics's net margin has surged by 99% YoY and by 65% QoQ
The operating margin has soared by 98% YoY and by 14% from the previous quarter
The company's net income has surged by 74% YoY and by 64% QoQ
BIOR's operating income is up by 10% QoQ and by 10% YoY
Growth
What is Biora Therapeutics's growth rate over time
Valuation
What is Biora Therapeutics stock price valuation
P/E
0.79
P/B
N/A
P/S
6.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.95
The EPS has soared by 105% from the previous quarter and by 102% YoY
The equity has declined by 19% since the previous quarter but it is up by 10% year-on-year
The P/S is 100% lower than the last 4 quarters average of 1357.7 and 99% lower than the 5-year quarterly average of 598.2
The revenue has grown by 3.7% from the previous quarter
Efficiency
How efficient is Biora Therapeutics business performance
The ROS has soared by 100% YoY and by 70% from the previous quarter
The return on assets has surged by 55% since the previous quarter and by 43% year-on-year
Dividends
What is BIOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIOR.
Financial health
How did Biora Therapeutics financials performed over time
Biora Therapeutics's total assets is 88% less than its total liabilities
BIOR's quick ratio has dropped by 83% year-on-year and by 75% since the previous quarter
The company's current ratio has shrunk by 82% YoY and by 75% QoQ
Biora Therapeutics's debt is 136% higher than its equity
Biora Therapeutics's debt has shrunk by 52% YoY and by 16% QoQ
The debt to equity has grown by 47% year-on-year and by 29% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.